Colorectal Cancer
Conditions
Brief summary
To observe the efficacy of PD-1 antibody JS001 in the treatment of participants with microsatellite instability-high (MSI-H) advanced or recurrent colorectal cancer, so as to provide sufficient evidence for MSI-H as a biomarker of PD-1/PD-L1 inhibitor.
Interventions
DRUGJS001
JS001 240mg, Q3W
Sponsors
Xu jianmin
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Fully understand the study and sign informed consent voluntarily; * Histologically confirmed advanced or recurrent colorectal cancer, and MSI detection identified MSI-H; * Patients who have previously received first-line or above chemotherapy or targeted therapy and failed to the treatment or experienced recurrence; * At least one measurable lesion (RECIST 1.1); * Agree to provide tumor tissue samples and Pathology reports related to the specimens; * Aged 18 to 75 years, gender not limited; * Eastern Cooperative Oncology Group(ECOG) performance status(PS) 0-1; 8. Expected survival ≥3 months; * Laboratory test values must meet the following standards within 7 days before enrollment; * Women of reproductive age must confirm that the serum pregnancy test is negative and agree to use effective contraceptive measures during the study drug use
Exclusion criteria
* Uncontrolled or symptomatic hypercalcemia; * Had major surgery or had not fully recovered from previous surgery within 4 weeks before enrollment; * central nervous system(CNS) metastases; * Bone metastases; * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once a month or more frequently) allow the patient to have a catheter indwelling; * Having a history of idiopathic pulmonary fibrosis, organic pneumonia; * Uncontrolled active infection, including but not limited to acute pneumonia; * Have other malignant tumors at the same time; * The patient has any active autoimmune diseases or a history of autoimmune diseases; * Liver diseases of known clinical significance, including active viral viral hepatitis, alcoholic hepatitis or other hepatitis, cirrhosis, fatty liver and hereditary liver diseases. * Previous use of anti-PD-1 antibody, anti-PD-l1 antibody, anti-PD-l2 antibody or anti-CTLA-4 antibody; * Patients with active tuberculosis (TB); * Received systemic immunosuppressive within 4 weeks prior to day 1 of the first cycle; * Pregnancy test positive; * Known human immunodeficiency virus (HIV) infection; * A history of severe allergy, anaphylaxis or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; * Those who are known to be allergic to biological drugs produced by hamster ovary cells in China, or to citric acid monohydrate, sodium citrate dihydrate, mannitol and polysorbate (components of the experimental drugs); * Patients who have previously received allogeneic stem cells or parenchymal organ transplantation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| objective response rate | 12 Weeks from the drug firstly being taken | The 12 week objective response will be measured according to RECIST v1.1 |
Countries
China
Contacts
Primary ContactJianmin Xu, MD
Outcome results
None listed